GWP GW Pharm.

 

TIDMGWP 
 
RNS Number : 8861N 
GW Pharmaceuticals PLC 
18 June 2010 
 

                             GW Pharmaceuticals plc 
                              ("GW" or "the Group") 
 
 
                                 Product Update 
 
Porton Down, UK, 18 June 2010: Consistent with previous guidance that a UK 
approval for Sativex is expected by the end of Q2 2010, GW confirms that it has 
just received formal notification of the grant of a product licence from MHRA 
for Sativex.  GW's marketing partner, Bayer Schering Pharma, will be announcing 
the formal UK launch of Sativex on Monday 21 June and further details will be 
provided at that time. 
 
 
 
Enquiries: 
 
+----------------------------------------+--------------------------+ 
| Financial Dynamics                     |        + 44 20 7831 3113 | 
+----------------------------------------+--------------------------+ 
| Ben Atwell / John Dineen               |                          | 
+----------------------------------------+--------------------------+ 
|                                        |                          | 
+----------------------------------------+--------------------------+ 
| Piper Jaffray Ltd                      |      +44 (0)20 3142 8700 | 
+----------------------------------------+--------------------------+ 
| Neil Mackison / Rupert Winckler        |                          | 
+----------------------------------------+--------------------------+ 
 
 
 
Notes to Editors 
 
About GW 
GW was founded in 1998 and listed on the AiM, a market of the London Stock 
Exchange, in June 2001. Operating under license from the UK Home Office, the 
company researches and develops cannabinoid pharmaceutical products for patients 
who suffer from a range of serious ailments, in particular multiple sclerosis 
and cancer pain. GW has assembled a large in-house scientific team with 
expertise in cannabinoid science as well as experience in the development of 
both plant-based prescription pharmaceutical products and medicines containing 
controlled substances. GW occupies a world leading position in cannabinoids and 
has developed an extensive international network of the most prominent 
scientists in the field. 
 
This news release may contain forward-looking statements that reflect GWs 
current expectations regarding future events, including development and 
regulatory clearance of the GW's products.  Forward-looking statements involve 
risks and uncertainties. Actual events could differ materially from those 
projected herein and depend on a number of factors, including (inter alia), the 
success of the GW's research strategies, the applicability of the discoveries 
made therein, the successful and timely completion of uncertainties related to 
the regulatory process, and the acceptance of Sativex  and other products by 
consumer and medical professionals. 
 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 MSCKKFDNNBKDDAD 
 

Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Jun 2024 to Jul 2024

Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Jul 2023 to Jul 2024